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Abstract: Breast cancer is a complex and heterogeneous 
disease and also one of the major cancer types among female 
worldwide. Fever range whole-body hyperthermia and curcumin 
as a single treatment have been tested against breast cancer and 
showed some promising anti-tumor effect. However, their 
combination as an effective anti- tumor treatment against breast 
cancer has never been explored. The effects of combined whole-
body fever range hyperthermia and curcumin on tumor growth 
was examined in this study. Mice were inoculated with EMT6 
cells subcutaneously and allocated to 4 treatment groups: (i) 
control (control), (ii) curcumin (50mg/kg bodyweight), (iii) twice 
fever range whole-body hyperthermia 39.0°C (± 0.5) for 15 
minutes, (iv) a combination of curcumin (50mg/kg bodyweight) 
and twice fever range whole-body hyperthermia 39.0°C (± 0.5) 
for 15 minutes. Following treatment, mice body weight and 
tumor volume were measured. The greatest tumor growth 
inhibition exhibited in combination treatment (68.45%, p<0.05) 
and showed no general toxicity. As conclusion, the combination 
treatment can be a potential anti-tumor treatment of breast 
cancer. 
 
Index Terms: breast cancer, curcumin, fever-range whole body 
hyperthermia (FRWBH). 
I. INTRODUCTION 
Breast cancer is the most common cancer occurring 
among women throughout the world. In Malaysia, breast 
cancer was accounted 32.1% of all cancer among females 
and the prevalence has increased from 2007 to 2011 [1]. 
Current treatments in breast cancer include surgery, 
chemotherapy, radiotherapy and hyperthermia as well 
hormone therapy. These treatments are usually combined, 
such as surgery with chemotherapy, radiotherapy with 
chemotherapy and hyperthermia with radiotherapy. Though 
these treatments are amenable, it is restricted by possible 
adverse effect due to artificial anticancer drugs such as 
diarrhoea, rash, mucosal inflammation, febrile neutropenia 
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Curcumin is a hydrophobic polyphenol, a dietary 
phytochemical and a principle active ingredient derived 
from turmeric.  It was first isolated by Vogel and Pelletier in 
1815, its chemical structure and synthesis confirmed by 
Lampe et al. in 1910 and 1913 [4]. Chemically, it is a bis-
α,β unsaturated β- diketone named (E,E)-1,7-bis(4-hydroxy-
3-methoxyphenyl)-1,6-heptadiene-5dione or commonly 
called diferuloylmethane [5]. Commercial curcumin is a 
mixture of curcuminoids, containing approximately 77% 
diferuloylmethane (Curcumin I), 17% demethoxycurcumin 
(Curcumin II), and 5% bisdemethoxycurcumin (Curcumin 
III) [4].  
Curcumin has chemopreventive and therapeutic activity 
against various breast cancer cell lines [6]–[8]. Besides, 
previous study of curcumin in vivo presented significant 
reduction of tumor multiplicity, prolongation of tumour-free 
survival inhibition of the tumor growth, reduced the tumor 
size and weight during the treatment [7]–[10]. 
Additionally, curcumin also used in combination with 
other modalities. The tumor growth in female CD1 nude 
mice suppressed by the combination treatment of curcumin 
(200mg/kg/day) and epigallocethun gallate (25mg/kg/day) 
for 10 weeks [11]. Further, study reported that combination 
of curcumin (50mg/kg) and metformin (80mg/kg) in 14 days 
showed the highest significant reduction in the tumour size 
[12]. While the combination of taxol with curcumin in the 
BT-474 xenograft model had an antitumour effect 
comparable with taxol and herceptin treatment [10]. 
On the other hand, hyperthermia is broadly referred as a 
condition where mean body temperature higher than normal. 
In medicine, hyperthermia therapy (HT) or thermotherapy is 
the procedure to elevate the temperature of a part of or the 
whole body above normal for a definite period of time, 
using external and internal heating device. Hyperthermia 
treatment temperatures in clinical procedure range between 
39–45 °C [13]. Hyperthermia is commonly applied as 
combination with various established cancer treatment 
modalities such as radiotherapy [14], chemotherapy [15], 
surgery and immunotherapy [16]. The temperature and 
duration of HT damages cells and enhances radiotherapy 
and chemotherapy sensitivity [17]. 
The cellular changes such as protein denaturation and 
aggregation, inducing cell cycle interruption and apoptosis, 
increasing membrane permeability, altering Ca2+ 
homeostasis and promoting intracellular accumulation of 
chemical agents show the efficiency of hyperthermia in 
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As well as, the cytotoxic effects of hyperthermia is 
including activation of the immune systems against tumor, 
enhancing drug delivery and improvement of oxygenation 
[18], [19]. This study aimed to investigate the efficacy of 
curcumin combined with fever range whole-body 
hyperthermia in suppressing breast cancer tumor growth. 
II. MATERIALS & METHODOLOGY 
Animals  
Animal care and use in this study was conducted 
according to standard ethical guidelines and experimental 
protocols approved by the Animal Ethics Committee of 
Universiti Kebangsaan Malaysia, approval number 
(UTM/2017/MAHEZA IRNA/22-NOV./884-NOV.-2017-
MARCH-2019). 
Female BALB/c mice (6-8 weeks old) [20] with 17-25g 
body weight was purchased from local university Animal 
Research Unit. Animals were housed in cage (max 5/cage) 
with 12-h dark and light cycles, fed standard laboratory diet 
and water ad libitum daily and bedding changed every two 
days. The mice allowed to acclimatize for at least 7 days 
before experiments. 
Selection of curcumin dose 
Dosage range between 50 ug/kg to 200mg/kg were 
effectively inhibit breast cancer growth as reported in 
previous studies on various animal model species [11], [21], 
[22]. However, curcumin dosage of 50mg/kg was used to 
Balb/c mice induced EMT6 breast cancer tumor size [12]. 
Therefore this study is used as reference.   
Selection of temperature and duration of fever range 
whole-body hyperthermia (FRWBH) treatment 
This study was initiated by the optimization of 
temperature and duration of FRWBH treatment conducted 
using water-filtered infrared-A (wIRA) by Hydrosun 
Medizintechnik GmbH device to observe the viability of 
mice under certain temperature of mild hyperthermia within 
the range of 39.0-40.0°C which commonly used in clinical 
procedure [16].  
Tumor inoculation 
EMT6 mouse mammary tumor cells were maintained in 
Waymouth‟s Media MB752/1 Liquid Medium (1x) Thermo 
Fisher [23] supplemented with 10% heat-inactivated Fetal 
Bovine Serum (FBS) Thermo Fisher and 1% antibiotics 
(100U/ml penicillin and 100μg/ml streptomycin). Cells  
were harvested using trypsin solution TrypLETM Express 
Enzyme (1x) without phenol red, washed, centrifuged and 
re-suspended in Phosphate Buffered Saline (PBS), at a 
density of 5 X 106 cells/ml [20]. Cells count performed 
using haemocytometer plate and the cells re-suspended in 
PBS. Each BALB/c mouse received 5x105 EMT6 cells in 
100µl PBS [24] injected subcutaneously at right flank. 
FRWBH treatment 
Whole body Fever Range hyperthermia (FRWBH) was 
conducted twice using water-filtered infrared-A (wIRA) by 
Hydrosun Medizintechnik GmbH device on day-17 and day- 
23 post inoculation. Mice were anesthetized with the 
mixture of ketamine (150 mg/kg) and xylazine (7.5 mg/kg) 
and hyperthermia treatment were conducted at 39°C (±0.5) 
maintained for up to 15 minutes. Rectal temperature 
monitored continuously in each mouse using small animal 
rectal thermostat probes [25] along the treatment (Figure 1). 
 
Fig. 1 Mice rectal temperature recorded during FRWBH 
treatment. Median rectal temperature of the mice during 
hyperthermia treatment was 39.05°C and mean rectal 
temperature of the mice was 38.17 °C. Approximately 12 
minutes required for the rectal temperature to reach 
39.0 °C (±0.5). 
General toxicity assessment 
Mice body weight recorded every other day after inoculation 
as a general indicator of toxicity. Drug-specific toxicities 
such as liver toxicity, renal toxicity, neurotoxicity were not 
measured in this study. 
Antitumor activity assessment 
Mice were randomly distributed into four groups (n=5 for 
each group). Group 1 received no treatment (CONTROL). 
Group 2 received 50mg/kg bwt curcumin orally (CUR) 
using oral gavage daily for 14 days starting day-14 post 
inoculation until day-27 post inoculation. Group 3 received 
whole-body hyperthermia treatment conducted at 39°C 
(±0.5) maintained for up to 15 minutes on day-17 and day-
23 post inoculation (FRWBH). Group 4 received both 
curcumin 50mg/kg bwt orally and hyperthermia treatment 
conducted at 39°C (±0.5) maintained for up to 15 minutes 
on day-17 and day-23 post inoculation (CUR+FRWBH). 
Summary of mice group allocation and the treatment 
received as shown in Table 1. Mice were sacrificed on day-
28 post inoculation. Tumor size was measured and recorded 
every other day using electronic caliper to determine the 
diameter [26]. Tumor volume was calculated according to 
the formula „tumor volume = 1/2(ab2)‟ in which „a‟ is the 
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Data analyzed using Graph Pad Prism Windows 5.00 and 
presented as mean ± SEM (standard error of mean). One-
way analysis of variance (ANOVA) was used to measure 
variations between different groups. Unpaired-samples t-test 
was used to examine the effects of different treatments on 
the tumor size and body weight. The level of significance 
was set at p < 0.05. 
III. RESULTS 
Selection of temperature and duration of fever range 
whole-body hyperthermia (FRWBH) treatment 
Each of experiment group for temperature optimization 
consist of two mice (n=2). All mice (n=2) were dead 
immediately after completion of FRWBH treatment of 40.0 
°C (± 0.5) for 30 minutes. The second group of mice is 
exposed to FRWBH treatment of 40.0 °C (± 0.5) for 15 
minutes. One mouse (n=1) dead a day after the treatment 
and another one (n=1) survived up to 14 days after the 
treatment. The result was similar for mice received FRWBH 
treatment of 39.0 °C (± 0.5) for 30 minutes. However, all 
mice (n=2) which received FRWBH treatment of 39.0°C (± 
0.5) for 15 minutes were survived more than 10 days after 
the treatment. Therefore, the temperature of 39.0°C (± 0.5) 
was selected as optimum temperature and duration of 15 
minutes as duration method for FRWBH treatment of this 
study. 
General toxicity assessment 
Table 2 shows the result for mice body weight for each 
group. Mice body weights recorded every other day as an 
indicator of general health and treatment-induced toxicity. 
Overall result shows there is significant different of mean 
body weight among the groups (p<0.0001) and weight 







Table. 2 Effect of 50mg/kg curcumin, FRWBH and 
combination of both on mice body weight. 
 
 
Antitumor activity assessment 
Tumor observed to continuous grow starting on day-7 and 
the time course for tumor volume changes after the initiation 
of treatment on day-14. Figure 2 shows results of the tumor 
growth profile for all groups during experiment. Mean 
tumor volume of the mice after 28 days was significantly 
different among groups (p=0.0042, p<0.01). Mice treated 
with CUR+FRWBH proved significantly delayed tumor 
growth as compared to curcumin and control. The tumor in 
control group grew progressively as compared to others 
group, while FRWBH demonstrated the greater tumor 
growth control among the group. 
Tumor inhibition rate for all treatment groups is shows in 
Figure 3. CUR+FRWBH inhibition rate is higher than 
curcumin with 68.45% and FRWBH has the highest 
inhibition rate. 
 
Mean tumor volume of the mice
























Fig. 2 Antitumor effect of curcumin combined with 
FRWBH in breast cancer-induced Balb/c mice. Mice 
injected subcutaneously with EMT6 cells and tumor was 
allowed to grow for 14 days before initiation of 
treatment. Values are the mean ± SEM of 5 mice. 
ANOVA p<0.01, p<0.05 compared with control, p<0.05 
compared to FRWBH alone. 
 
Group Treatment received 
CONTROL No treatment received. 
CUR Orally 50mg/kg daily (day-14 to day-27 post 
inoculation). 
FRWBH Whole-body hyperthermia treatment 
conducted at 39°C (±0.5) maintained for up 




Orally 50mg/kg daily (day-14 to day-27 post 
inoculation  and Whole-body hyperthermia 
treatment conducted at 39°C (±0.5) 
maintained for up to 15 minutes on day-17 
and day-23 post inoculation. 
 
Group Mean body 
weight (g) 




CONTROL 24.21 ± 0.14 - 1.21 ± 0.14 - 
CUR 24.53 ± 0.16 0.1443 1.13 ± 0.16 0.5567 
FRWBH 23.96 ± 0.13 0.1975 0.36 ± 0.13 0.0004 
CUR + 
FRWBH 
26.64 ± 0.13 <0.0001 0.64 ±0.13  0.0089 
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Fig. 3 Tumor growth inhibition rate of treatment 
compared to control. 
IV. DISCUSSION 
Breast cancer is one of the main cancer among female 
population worldwide. Due to the elevated death rate related 
with cancer and severe side effects of chemotherapy and 
radiation therapy, many cancer patients seek alternative 
complementary and alternative medicines (CAM) as method 
of treatment. CAM have related with natural herbal 
medicines and herbal plant, which are alleged to various 
biological and molecular mechanisms by inhibiting the 
growth of cancer. Hyperthermia is commonly applied as 
combination with various established cancer treatment 
modalities such as radiotherapy, chemotherapy, surgery and 
immunotherapy, effectively increased antitumor effect. 
Thus, this study is conducted to search for new alternative 
treatment of breast cancer by funds of curcumin combined 
with hyperthermia treatment.  
In this study, each group received single treatment of 
curcumin or hyperthermia and combination of both to see 
the efficacy of each treatment towards the tumor growth and 
animal health. Mean body weight of treated mice were 
higher than control mice and there were weight gained in all 
groups up to 28 days of experiment that may due to tumor 
growth. It is better than the decline in body weight due to 
toxicity [27]. General observation of animal health showed 
that the treatments were well tolerated by the mice and non-
toxic to the mice. 
The results of our study towards tumor volume of mice 
suggested that FRWBH was effectively reduced tumor size 
with the highest inhibition rate (86.14%). The findings are 
equivalent with previous studies which stated hyperthermia 
was cytotoxic to breast cancer cells [30], [31]. However, 
there was rapid tumor growth few days before experiment 
ended which reinforced that hyperthermia as single-
treatment modality had low response rate and short duration 
limits [16], [32]. 
Even though the tumor inhibition rate in combined group 
was lower than FRWBH group, our results show the tumor 
growth in CUR+FRWBH group was plateau few days 
before end of experiment compared to others treatment 
group, indicating the combination treatment had better effect 
on tumor growth suppression compared to CUR and 
FRWBH treatments. The findings are in line with previous 
studies that combination of radiotherapy (RT), 
chemotherapy (CT) or RT plus CT treatment with 
hyperthermia were better, compared with the same treatment 
without hyperthermia in mice and human [13], [25], [33]. 
In summary, we demonstrated that FRWBH combined 
with curcumin was beneficial against solid tumor than 
treatment with FRWBH or curcumin alone, with respect to 
inhibition of tumor growth without general toxicity effect.  
V. CONCLUSION 
As from this perspective, we suggest that combination 
treatment with FRWBH and curcumin is actually useful as 
alternative antitumor treatment for breast cancer. However, 
further study with larger sample and various temperature 
and duration of whole body fever range hyperthermia should 
be conducted in the future in regards to explore the 
mechanism of action of this combination treatment.  
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